MODELING THE POTENTIAL PUBLIC HEALTH IMPACT OF INTRODUCING ONE-DOSE BOOSTER MENINGOCOCCAL B VACCINATION (4CMENB) FOR ADOLESCENTS IN ENGLAND, SPAIN AND ITALY
Author(s)
Irshaad R. Jansen1, Sara Boccalini, PhD2, Paolo Bonanni, PhD2, Stefano Castagna, PhD3, Federico Martinón-Torres, PhD4, Nana Opoku-Ansah, MSc5, LAURA AMANDA VALLEJO APARICIO, MSc6, Phil Watson, PhD5, Thatiana de Jesus Pereira Pinto, PhD7, Pavo Marijic, MSc8, Justyna Zawieja, MSc9.
1Associate Director Value Evidence, GSK, Elsene, Belgium, 2University of Florence, Florence, Italy, 3GSK, Verona, Italy, 4Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain, 5GSK, London, United Kingdom, 6GSK, PALMA DE MALLORCA, Spain, 7gsk, Brussels, Belgium, 8GSK, München, Germany, 9Inizio Ignite Putnam, Krakow, Poland.
1Associate Director Value Evidence, GSK, Elsene, Belgium, 2University of Florence, Florence, Italy, 3GSK, Verona, Italy, 4Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain, 5GSK, London, United Kingdom, 6GSK, PALMA DE MALLORCA, Spain, 7gsk, Brussels, Belgium, 8GSK, München, Germany, 9Inizio Ignite Putnam, Krakow, Poland.
OBJECTIVES: Invasive meningococcal disease (IMD) is an uncommon, severe infection with substantial mortality and sequelae. Routine infant/toddler MenB and toddler/adolescent MenACWY immunization significantly reduces disease burden. However, many countries have an unmet need, as adolescents/young adults experience a second IMD peak (predominantly MenB), for which no MenB vaccination program exists. The public health impact of introducing 4CMenB vaccination with adolescent MenACWY vaccination versus no additional vaccination was assessed in England, Spain and Italy.
METHODS: A dynamic transmission model simulated single-year age-stratified cohorts (0-99 years) for IMD incidence over a 30-year time horizon, calculating serogroup B cases, sequelae and deaths avoided. Model inputs used real-world vaccine effectiveness, country-specific epidemiology and coverage to estimate IMD burden in 15-19/20-24-year-olds (YO). Adolescent 4CMenB, given with MenACWY, was compared with SOC. One-dose 4CMenB was modelled for adolescents who received pediatric 4CMenB and two-dose 4CMenB for naïve individuals. First-dose/second-dose adolescent 4CMenB coverage rates (assumed from MenACWY and human papillomavirus vaccination rates) were 73%/65% (England), 88%/81% (Spain), and 62%/48% (Italy).
RESULTS: Adding adolescent 4CMenB vaccination was estimated to reduce serogroup B cases among 15-24YO by 22-35% across the countries; and among 15-19YO/20-24YO, by 43%/24% (England); 44%/9% (Spain); and 34%/11% (Italy), respectively. IMD sequelae in adolescents were reduced by 16-29% overall, and among 15-19YO/20-24YO by 33%/19% (England); 36%/7% (Spain); and 25%/7% (Italy), respectively. Serogroup B deaths were reduced by 21-36% overall; and among 15-19YO/20-24YO, by 40%/24% (England); 44%/9% (Spain); and 34%/11% (Italy).
CONCLUSIONS: Introducing routine adolescent one-dose and two-dose 4CMenB in England, Spain and Italy was estimated to improve public health, reducing morbidity and mortality and improving long-term outcomes. Higher coverage could improve results. With higher pediatric 4CMenB coverage, comparatively fewer adolescent doses are needed, potentially improving adolescent compliance rates and leading to greater MenB protection.
METHODS: A dynamic transmission model simulated single-year age-stratified cohorts (0-99 years) for IMD incidence over a 30-year time horizon, calculating serogroup B cases, sequelae and deaths avoided. Model inputs used real-world vaccine effectiveness, country-specific epidemiology and coverage to estimate IMD burden in 15-19/20-24-year-olds (YO). Adolescent 4CMenB, given with MenACWY, was compared with SOC. One-dose 4CMenB was modelled for adolescents who received pediatric 4CMenB and two-dose 4CMenB for naïve individuals. First-dose/second-dose adolescent 4CMenB coverage rates (assumed from MenACWY and human papillomavirus vaccination rates) were 73%/65% (England), 88%/81% (Spain), and 62%/48% (Italy).
RESULTS: Adding adolescent 4CMenB vaccination was estimated to reduce serogroup B cases among 15-24YO by 22-35% across the countries; and among 15-19YO/20-24YO, by 43%/24% (England); 44%/9% (Spain); and 34%/11% (Italy), respectively. IMD sequelae in adolescents were reduced by 16-29% overall, and among 15-19YO/20-24YO by 33%/19% (England); 36%/7% (Spain); and 25%/7% (Italy), respectively. Serogroup B deaths were reduced by 21-36% overall; and among 15-19YO/20-24YO, by 40%/24% (England); 44%/9% (Spain); and 34%/11% (Italy).
CONCLUSIONS: Introducing routine adolescent one-dose and two-dose 4CMenB in England, Spain and Italy was estimated to improve public health, reducing morbidity and mortality and improving long-term outcomes. Higher coverage could improve results. With higher pediatric 4CMenB coverage, comparatively fewer adolescent doses are needed, potentially improving adolescent compliance rates and leading to greater MenB protection.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE750
Topic
Clinical Outcomes, Economic Evaluation, Methodological & Statistical Research
Disease
Infectious Disease (non-vaccine), Vaccines